An N-terminal CDC42 T43I variant reveals the mechanism of pyrin inflammasome activation
Scientists solved a long-standing puzzle about how a specific protein normally prevents dangerous inflammation, revealing why certain mutations trigger severe autoinflammatory disease.
This Science Immunology study—a companion to PMID 42566500—used a patient CDC42 T43I variant to reveal that CDC42 directly suppresses pyrin inflammasome activation by binding the pyrin B30.2 domain, and that loss of this interaction causes constitutive hyperactivation leading to severe autoinflammatory disease. The findings mechanistically resolve a long-standing puzzle about pyrin regulation and provide a molecular framework for understanding the spectrum of pyrin-associated autoinflammatory diseases (PAADs) beyond classical FMF.
What the study was
- Study design
- mechanistic
- Population
- Patients with CDC42 T43I germline variant (autoinflammatory disease); patient-derived cell models
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Science Immunology
Why it surfaced
Published alongside companion paper 42566500 in Science Immunology; high novelty—CDC42 as a pyrin regulator is new biology with direct clinical implications for PAAD diagnosis and therapy; large multi-national author group (Japan-France-Italy) suggests robust validation; rare autoinflammatory disease with high unmet need for better genetic diagnosis tools.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.